tirzepatide cardiovascular outcome outcomes trial Matches Dulaglutide in Large CV Trial: SURPASS-CVOT UC Irvine researchers project cardiac – Risk of major adverse cardiovascular

Glucagon Receptor A receptor that, when activated in the context of triple agonism, increases energy expenditure and fat oxidation

Glucagon's Effects on Nerves: Glucagon receptors exist throughout the nervous system Activation affects nerve cell metabolism May alter nerve excitability or signal transmission Could disrupt normal sensory processing Supporting Evidence: Dysesthesia only occurs with retatrutide (which has glucagon component) Dose-dependent (higher glucagon activation = more dysesthesia) Not seen in Phase 2 at lower doses (less glucagon effect) Theory 2: Rapid Weight Loss and Nerve Changes Retatrutide produces the fastest, most substantial weight loss of any obesity medication 28.7% at 68 weeks (TRIUMPH-4) and 28.3% at 80 weeks (TRIUMPH-1)

Start with activities you enjoy

During this initial phase, you may experience mild gastrointestinal symptoms such as reduced appetite, mild nausea, occasional bloating, or changes in bowel habits